pteridines has been researched along with bortezomib in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Elemento, O; Houghtaling, BR; Kapoor, TM; Wacker, SA | 1 |
| Bertomeu, T; Bucur, O; Dewar, R; Goganau, I; Khosravi-Far, R; Pennarun, B; Petrescu, SM; Stancu, AL | 1 |
| Duyster, J; Engelhardt, M; Felthaus, J; Follo, M; Greil, C; Klingner, K; Schnerch, D; Schüler, J; Wäsch, R; Wider, D | 1 |
| Chantry, AD; Down, JM; Evans, HR; Green, AC; Hudson, K; Lath, D; Lawson, MA; Owen, R; Paton-Hough, J; Reilly, GC; Walkley, B | 1 |
4 other study(ies) available for pteridines and bortezomib
| Article | Year |
|---|---|
Using transcriptome sequencing to identify mechanisms of drug action and resistance.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Cycle Proteins; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Pyrazines; Sequence Analysis, DNA; Transcriptome | 2012 |
Combination of bortezomib and mitotic inhibitors down-modulate Bcr-Abl and efficiently eliminates tyrosine-kinase inhibitor sensitive and resistant Bcr-Abl-positive leukemic cells.
Topics: Benzamides; Boronic Acids; Bortezomib; Caspases; Cell Death; Cell Line, Tumor; Dasatinib; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Fusion Proteins, bcr-abl; Heterocyclic Compounds, 2-Ring; Humans; Imatinib Mesylate; JNK Mitogen-Activated Protein Kinases; Leukemia; Mitosis; Models, Biological; p38 Mitogen-Activated Protein Kinases; Paclitaxel; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Pteridines; Pyrazines; Pyrimidines; Signal Transduction; STAT5 Transcription Factor; Thiazoles | 2013 |
Proteasome inhibition enhances the efficacy of volasertib-induced mitotic arrest in AML in vitro and prolongs survival in vivo.
Topics: Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cell Cycle Proteins; Cell Line, Tumor; Cyclin B; Cytarabine; Frail Elderly; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Mitosis; Polo-Like Kinase 1; Proteasome Inhibitors; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Treatment Outcome; Xenograft Model Antitumor Assays | 2017 |
TGFβ Inhibition Stimulates Collagen Maturation to Enhance Bone Repair and Fracture Resistance in a Murine Myeloma Model.
Topics: Alkaline Phosphatase; Animals; Bone Remodeling; Bortezomib; Cancellous Bone; Collagen; Disease Models, Animal; Female; Fractures, Bone; Green Fluorescent Proteins; Humans; Lenalidomide; Mesenchymal Stem Cells; Mice; Mice, SCID; Multiple Myeloma; Organ Size; Osteoblasts; Osteoclasts; Parathyroid Hormone-Related Protein; Pteridines; Transforming Growth Factor beta; Vascular Endothelial Growth Factor A; Wound Healing; X-Ray Microtomography | 2019 |